Fig. 7
From: SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer
SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.
Fig. 7 | Oncogene
From: SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer
SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.
